How much revenue did Soligenix generate this year?
Soligenix has achieved a revenue of 519,690 USD this year.
Soligenix Revenue 2024
Soligenix Revenue
519,690 USD
Ticker
SNGX
ISIN
US8342233074
WKN
A2AS7Q
In 2024, Soligenix's sales reached 519,690 USD, a -38.08% difference from the 839,360 USD sales recorded in the previous year.
The Soligenix Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 0.92 | 10,60 |
| 2025e | 0.92 | 10,60 |
| 2024e | 0.52 | 18,72 |
| 2023 | 0.84 | 11,59 |
| 2022 | 0.95 | 42,11 |
| 2021 | 0.82 | 12,20 |
| 2020 | 2.36 | 22,88 |
| 2019 | 4.63 | 22,89 |
| 2018 | 5.24 | 12,21 |
| 2017 | 5.43 | 20,63 |
| 2016 | 10.45 | 19,33 |
| 2015 | 8.77 | 21,55 |
| 2014 | 7.04 | 24,57 |
| 2013 | 3.22 | 21,12 |
| 2012 | 3.14 | 17,52 |
| 2011 | 7.66 | 72,45 |
| 2010 | 1.95 | 15,90 |
| 2009 | 2.82 | 47,16 |
| 2008 | 2.31 | 18,18 |
| 2007 | 1.26 | 25,40 |
| 2006 | 2.31 | 15,15 |
| 2005 | 3.08 | 32,79 |
| 2004 | 1 | 6,00 |
Soligenix Revenue, EBIT, Net Income US8342233074 · A2AS7Q
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Soligenix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Soligenix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Soligenix’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Soligenix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Soligenix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Soligenix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Soligenix’s growth potential.
Soligenix Revenue, EBIT and net profit per share
| Date | Soligenix Revenue | Soligenix EBIT | Soligenix Net Income |
|---|---|---|---|
| 2026e | 918,000 undefined | -10.51 M undefined | -11.47 M undefined |
| 2025e | 918,000 undefined | -8.85 M undefined | -11.78 M undefined |
| 2024e | 519,690 undefined | -8.09 M undefined | -13.94 M undefined |
| 2023 | 839,360 undefined | -7.7 M undefined | -6.14 M undefined |
| 2022 | 950,000 undefined | -14.24 M undefined | -13.8 M undefined |
| 2021 | 820,000 undefined | -13.1 M undefined | -12.55 M undefined |
| 2020 | 2.36 M undefined | -18.59 M undefined | -17.69 M undefined |
| 2019 | 4.63 M undefined | -10.54 M undefined | -9.36 M undefined |
| 2018 | 5.24 M undefined | -9.06 M undefined | -8.9 M undefined |
| 2017 | 5.43 M undefined | -7.59 M undefined | -7.15 M undefined |
| 2016 | 10.45 M undefined | -5.71 M undefined | -3.25 M undefined |
| 2015 | 8.77 M undefined | -7.11 M undefined | -7.83 M undefined |
| 2014 | 7.04 M undefined | -10.76 M undefined | -6.71 M undefined |
| 2013 | 3.22 M undefined | -7.16 M undefined | -10.06 M undefined |
| 2012 | 3.14 M undefined | -4.69 M undefined | -4.16 M undefined |
| 2011 | 7.66 M undefined | -2.96 M undefined | -2.38 M undefined |
| 2010 | 1.95 M undefined | -7.88 M undefined | -7.39 M undefined |
| 2009 | 2.82 M undefined | -6.05 M undefined | -6.03 M undefined |
| 2008 | 2.31 M undefined | -3.46 M undefined | -3.42 M undefined |
| 2007 | 1.26 M undefined | -6.33 M undefined | -6.16 M undefined |
| 2006 | 2.31 M undefined | -6.4 M undefined | -8.16 M undefined |
| 2005 | 3.08 M undefined | -4.68 M undefined | -4.72 M undefined |
| 2004 | 1 M undefined | -5.92 M undefined | -6.38 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 1 M USD | -5.92 M USD | -6.38 M USD |
| 2005 | 3.08 M USD | -4.68 M USD | -4.72 M USD |
| 2006 | 2.31 M USD | -6.4 M USD | -8.16 M USD |
| 2007 | 1.26 M USD | -6.33 M USD | -6.16 M USD |
| 2008 | 2.31 M USD | -3.46 M USD | -3.42 M USD |
| 2009 | 2.82 M USD | -6.05 M USD | -6.03 M USD |
| 2010 | 1.95 M USD | -7.88 M USD | -7.39 M USD |
| 2011 | 7.66 M USD | -2.96 M USD | -2.38 M USD |
| 2012 | 3.14 M USD | -4.69 M USD | -4.16 M USD |
| 2013 | 3.22 M USD | -7.16 M USD | -10.06 M USD |
| 2014 | 7.04 M USD | -10.76 M USD | -6.71 M USD |
| 2015 | 8.77 M USD | -7.11 M USD | -7.83 M USD |
| 2016 | 10.45 M USD | -5.71 M USD | -3.25 M USD |
| 2017 | 5.43 M USD | -7.59 M USD | -7.15 M USD |
| 2018 | 5.24 M USD | -9.06 M USD | -8.9 M USD |
| 2019 | 4.63 M USD | -10.54 M USD | -9.36 M USD |
| 2020 | 2.36 M USD | -18.59 M USD | -17.69 M USD |
| 2021 | 820,000 USD | -13.1 M USD | -12.55 M USD |
| 2022 | 950,000 USD | -14.24 M USD | -13.8 M USD |
| 2023 | 839,360 USD | -7.7 M USD | -6.14 M USD |
| 2024e | 519,690 USD | -8.09 M USD | -13.94 M USD |
| 2025e | 918,000 USD | -8.85 M USD | -11.78 M USD |
| 2026e | 918,000 USD | -10.51 M USD | -11.47 M USD |
Soligenix stock margins US8342233074 · A2AS7Q
The Soligenix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Soligenix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Soligenix.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Soligenix's sales revenue. A higher gross margin percentage indicates that the Soligenix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Soligenix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Soligenix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Soligenix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Soligenix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Soligenix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Soligenix Margin History
| Soligenix Gross margin | Soligenix Profit margin | Soligenix EBIT margin | Soligenix Profit margin |
|---|---|---|---|
| 2026e | 11.59 % | -1,144.44 % | -1,248.93 % |
| 2025e | 11.59 % | -963.61 % | -1,283.13 % |
| 2024e | 11.59 % | -1,557.11 % | -2,682.75 % |
| 2023 | 11.59 % | -917.12 % | -731.6 % |
| 2022 | 42.11 % | -1,498.95 % | -1,452.63 % |
| 2021 | 12.2 % | -1,597.56 % | -1,530.49 % |
| 2020 | 22.88 % | -787.71 % | -749.58 % |
| 2019 | 22.89 % | -227.65 % | -202.16 % |
| 2018 | 12.21 % | -172.9 % | -169.85 % |
| 2017 | 20.63 % | -139.78 % | -131.68 % |
| 2016 | 19.33 % | -54.64 % | -31.1 % |
| 2015 | 21.55 % | -81.07 % | -89.28 % |
| 2014 | 24.57 % | -152.84 % | -95.31 % |
| 2013 | 21.12 % | -222.36 % | -312.42 % |
| 2012 | 17.52 % | -149.36 % | -132.48 % |
| 2011 | 72.45 % | -38.64 % | -31.07 % |
| 2010 | 15.9 % | -404.1 % | -378.97 % |
| 2009 | 47.16 % | -214.54 % | -213.83 % |
| 2008 | 18.18 % | -149.78 % | -148.05 % |
| 2007 | 25.4 % | -502.38 % | -488.89 % |
| 2006 | 15.15 % | -277.06 % | -353.25 % |
| 2005 | 32.79 % | -151.95 % | -153.25 % |
| 2004 | 6 % | -592 % | -638 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 6 % | -592 % | -638 % |
| 2005 | 32.79 % | -151.95 % | -153.25 % |
| 2006 | 15.15 % | -277.06 % | -353.25 % |
| 2007 | 25.4 % | -502.38 % | -488.89 % |
| 2008 | 18.18 % | -149.78 % | -148.05 % |
| 2009 | 47.16 % | -214.54 % | -213.83 % |
| 2010 | 15.9 % | -404.1 % | -378.97 % |
| 2011 | 72.45 % | -38.64 % | -31.07 % |
| 2012 | 17.52 % | -149.36 % | -132.48 % |
| 2013 | 21.12 % | -222.36 % | -312.42 % |
| 2014 | 24.57 % | -152.84 % | -95.31 % |
| 2015 | 21.55 % | -81.07 % | -89.28 % |
| 2016 | 19.33 % | -54.64 % | -31.1 % |
| 2017 | 20.63 % | -139.78 % | -131.68 % |
| 2018 | 12.21 % | -172.9 % | -169.85 % |
| 2019 | 22.89 % | -227.65 % | -202.16 % |
| 2020 | 22.88 % | -787.71 % | -749.58 % |
| 2021 | 12.2 % | -1,597.56 % | -1,530.49 % |
| 2022 | 42.11 % | -1,498.95 % | -1,452.63 % |
| 2023 | 11.59 % | -917.12 % | -731.6 % |
| 2024e | 11.59 % | -1,557.11 % | -2,682.75 % |
| 2025e | 11.59 % | -963.61 % | -1,283.13 % |
| 2026e | 11.59 % | -1,144.44 % | -1,248.93 % |
Soligenix Aktienanalyse
What does Soligenix do?
Soligenix Inc. is a biopharmaceutical company specialized in the development of treatment and prevention methods for serious diseases. It was founded in 1987 and is headquartered in Princeton, New Jersey. The business model of Soligenix Inc. is based on the research and development of innovative therapies for diseases that are currently difficult to treat or have no known cure. The company's research and development focus on three core areas: vaccines, cancer therapies, and rare diseases. In the field of vaccines, Soligenix Inc. has focused on developing therapies against biological threats such as anthrax, smallpox, or botulinum toxin-like toxins. These threats are not only a potential danger to national security but can also occur in the form of natural disasters or terrorist attacks. Soligenix Inc. has several promising vaccine candidates in clinical trials, including an anthrax vaccine that works faster and safer than currently available vaccines. In the field of cancer therapy, the company focuses on developing new immunotherapies for the treatment of solid tumors. Soligenix Inc. uses a technology platform called "RiVax" based on the inactivation of botulinum toxin. This platform has already proven promising in redirecting the body's immune system to tumor cells and killing them. As the last core area, the company is dedicated to the treatment of rare diseases that are often overlooked and insufficiently treated. Soligenix Inc. has already developed a promising candidate for the treatment of oropharyngeal candidiasis (fungal infections in the mouth and throat) and is in phase III clinical trials. Overall, Soligenix Inc. has developed a range of promising products in various stages of clinical trials. In addition to the mentioned candidates, the company has also developed a promising treatment for relieving the side effects of cancer chemotherapy. This product called SGX942 is currently in phase III clinical trials. In addition to ongoing clinical studies, Soligenix Inc. has also established strong partnerships with government organizations such as the US National Institutes of Health or the Biomedical Advanced Research and Development Authority (BARDA). These partnerships are important to secure funding for ongoing research projects and allow the company to bring its products to market quickly. Soligenix Inc. has experienced strong growth in recent years and has established itself as a key player in the biopharmaceutical industry. The company has received several awards for its research work and innovation potential in the past and seems to be on a good path to bring further groundbreaking therapies to the market. Soligenix ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Soligenix's Sales Figures
The sales figures of Soligenix originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Soligenix’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Soligenix's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Soligenix’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Soligenix stock
How much was the turnover of the company Soligenix compared to the previous year?
The revenue of Soligenix has increased by -38.08% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Soligenix?
The revenue of Soligenix is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Soligenix measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Soligenix so important for investors?
The revenue of Soligenix is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Soligenix pay?
Over the past 12 months, Soligenix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soligenix is expected to pay a dividend of 0 USD.
What is the dividend yield of Soligenix?
The current dividend yield of Soligenix is .
When does Soligenix pay dividends?
Soligenix pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Soligenix?
Soligenix paid dividends every year for the past 0 years.
What is the dividend of Soligenix?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Soligenix located?
Soligenix is assigned to the 'Health' sector.
Wann musste ich die Aktien von Soligenix kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Soligenix from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Soligenix pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Soligenix in the year 2023?
In the year 2023, Soligenix distributed 0 USD as dividends.
In which currency does Soligenix pay out the dividend?
The dividends of Soligenix are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Soligenix stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Soligenix
Our stock analysis for Soligenix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soligenix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
